Search

Regulatory drug evaluations and expedited review initiatives: EU and US perspectives

The European Medicines Agency (EMA) and United States Food and Drug Administration (FDA) each conduct independent assessments of benefit-risk profile when evaluating applications to market new or modified medicines, and their respective decision-making is guided by distinct legislation, procedures and...

A career in uveitis

As he retires from clinical practice, the author looks back on his long career in uveitis and how care of these patients has changed dramatically since his days as an undergraduate. My trainees and fellows are often bored by my...

Across the globe and into the world of international eye grading

Decades have passed and the influence of analysing fundus images by grading consultants and retinal image specialists has grown worldwide. Their job is to specialise in assessing hundreds of diagnosed eye disease disorders and to read thousands of eye images,...

Retinoblastoma management update (part 2): treatment, screening and surveillance, long-term follow-up and new developments

Retinoblastoma treatment requires significant multidisciplinary input, but early detection through raising awareness remains key to improving outcomes. In the second article of a two-part series, Manoj Parulekar discusses retinoblastoma management, screening and research. This article has been published in two...

The future of multi-professional working in eye care

How the integration of service improvement technology, and health promotion will allow eye care professionals to overcome current and future challenges. The future of eye care in the UK is at a precipice. Hospital attendances are increasing year on year,...

Childhood glaucoma

When a child is given a diagnosis of glaucoma, the impact upon that child and their family is enormous; equivalent to the diagnosis of a cancer [14]. This article outlines the knowledge, techniques and approaches that offer solutions to the...

The last three patients: dermatology (Patient Three)

For the third and final reflection in this series (see Part 1 and Part 2), Professor Jonathan Rees recounts his experience of a patient with cancer who was failed by the NHS, and how their inadequate treatment illuminates some issues...